Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Newest in this topic

  1. Analysis of clinical failure of anti-tau and anti-synuclein antibodies in neurodegeneration using a quantitative systems pharmacology model 2023-09-01
  2. Computer-Aided Drug Design of β-Secretase, γ-Secretase and Anti-Tau Inhibitors for the Discovery of Novel Alzheimer's Therapeutics 2020-01-21
  3. AAV-mediated expression of anti-tau scFvs decreases tau accumulation in a mouse model of tauopathy 2017-04-17

Studies

8 studies carry this tag.

Date range

2002 to 2023

Top journals

  • Acta neuropathologica 1
  • Human vaccines 1
  • International journal of molecular sciences 1
  • Journal of Alzheimer's disease : JAD 1
  • Neuroscience letters 1

8 journals in all.

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Analysis of clinical failure of anti-tau and anti-synuclein antibodies in neurodegeneration using a quantitative systems pharmacology model

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Scientific reports 2023-09-01 Drug development

    Misfolded proteins in Alzheimer's disease and Parkinson's disease follow a well-defined connectomics-based spatial progression.

  2. Computer-Aided Drug Design of β-Secretase, γ-Secretase and Anti-Tau Inhibitors for the Discovery of Novel Alzheimer's Therapeutics

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. International journal of molecular sciences 2020-01-21 Treatments

    Aging-associated neurodegenerative diseases, which are characterized by progressive neuronal death and synapses loss in human brain, are rapidly growing affecting millions of people globally.

  3. AAV-mediated expression of anti-tau scFvs decreases tau accumulation in a mouse model of tauopathy

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. The Journal of experimental medicine 2017-04-17 Drug development

    Tauopathies are characterized by the progressive accumulation of hyperphosphorylated, aggregated forms of tau.

  4. Alzheimer's Disease: Characterization of the Brain Sites of the Initial Tau Cytoskeletal Pathology Will Improve the Success of Novel Immunological Anti-Tau Treatment Approaches

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Journal of Alzheimer's disease : JAD 2017-01-01 Drug development

    Alzheimer's disease (AD) represents the most frequent neurodegenerative disease of the human brain worldwide.

  5. Combination Therapy of Anti-Tau and Anti-Amyloid Drugs for Disease Modification in Early-stage Alzheimer's Disease: Socio-economic Considerations Modeled on Treatments for Tuberculosis, HIV/AIDS and Breast Cancer

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. The journal of prevention of Alzheimer's disease 2016-01-01 Drug development

    Current drugs for treatment of mild to severe dementia of the Alzheimer's type include cholinesterase inhibitors and the NMDA non-competitive receptor antagonist memantine.

  6. Curcumin-induced upregulation of the anti-tau cochaperone BAG2 in primary rat cortical neurons

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Neuroscience letters 2013-09-11 Drug development

    Alzheimer's disease (AD) is a progressive, neurodegenerative disease characterized by extracellular deposits of amyloid beta (Aβ) protein and intracellular neurofibrillary tangles of hyperphosphorylated tau protein.

  7. Anti-tau oligomers passive vaccination for the treatment of Alzheimer disease

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Human vaccines 2010-11-01 Drug development

    The aggregation and accumulation of the microtubule-associated protein (Tau) is a pathological hallmark of Alzheimer's disease (AD) and many neurodegenerative diseases.

  8. Anti-tau phospho-specific Ser262 antibody recognizes a variety of abnormal hyper-phosphorylated tau deposits in tauopathies including Pick bodies and argyrophilic grains

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. Acta neuropathologica 2002-08-30 Drug development

    The rabbit polyclonal anti-tau phospho-specific Ser262 antibody (577814 Calbiochem) recognizes disease-specific band patterns on Western blots of sarkosyl-insoluble fractions in Alzheimer's disease (AD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), argyrophilic grain disease (AGD) and Pick's disease (PiD): four bands of 74/72, 68, 64 and 60 kDa in AD, two bands of 68 and 64 kDa in PSP, CBD and AGD, and two bands of 64 and 60 kDa in PiD.

All topic tags with their study counts